{"doi":"10.1016/j.jdin.2022.12.006","title":"Management of silicone granuloma: A systematic review","abstract":"To the Editor: In 2017, the US Food and Drug Administration issued warnings against injectable silicone for cosmetic enhancement.1FDA warns against injectable silicone and dermal fillers for large-scale body contouring and enhancement. US Food & Drug Administration.https://www.fda.gov/consumers/consumer-updates/fda-warns-against-injectable-silicone-and-dermal-fillers-large-scale-body-contouring-and-enhancementDate accessed: May 26, 2022Google Scholar Despite well-established associations between silicone injection and granuloma formation, current evidence-based management guidelines are limited.2Kassamali B. Kus K.J. Min M.S. et al.Characteristics and treatment of silicone granulomas: a retrospective multicenter cohort of 21 patients.JAAD Int. 2021; 3: 111-114https://doi.org/10.1016/j.jdin.2021.03.007Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar,3Jones D.H. Fitzgerald R. Cox S.E. et al.Preventing and treating adverse events of injectable fillers: evidence-based recommendations from the American Society for Dermatologic Surgery Multidisciplinary Task Force.Dermatol Surg. 2021; 47: 214-226https://doi.org/10.1097/DSS.0000000000002921Crossref PubMed Scopus (11) Google Scholar The current guidelines by the American Society of Dermatologic Surgery recommend “intralesional injections of 5-FU (5-fluorouracil) mixed with triamcinolone at monthly intervals” for the treatment of silicone granulomas, with low certainty of evidence.3Jones D.H. Fitzgerald R. Cox S.E. et al.Preventing and treating adverse events of injectable fillers: evidence-based recommendations from the American Society for Dermatologic Surgery Multidisciplinary Task Force.Dermatol Surg. 2021; 47: 214-226https://doi.org/10.1097/DSS.0000000000002921Crossref PubMed Scopus (11) Google Scholar We aimed to characterize treatments and associated outcomes for silicone granulomas following silicone injection. This systematic review was registered on the International prospective register of systematic reviews (PROSPERO) (CRD42021260380) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (Supplementary Material 1, available via Mendeley at https://data.mendeley.com/datasets/nvmxbjdnbn/2). PubMed or MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE, Scopus, and Web of Science were searched on April 13, 2022, for studies that reported treatment outcomes for silicone granulomas secondary to silicone injections (Supplementary Table I, available via Mendeley at https://data.mendeley.com/datasets/nvmxbjdnbn/2). The outcome of interest was silicone granuloma response following treatment with the described intervention. The classification of outcomes (complete response, partial response, stable disease, or disease worsening) was determined by the authors based on the manuscripts’ results. The search identified 901 studies, of which 231 were subjected to full-text evaluation; 93 studies met the inclusion criteria and were included for data analysis (Supplementary Fig 1, available via Mendeley at https://data.mendeley.com/datasets/nvmxbjdnbn/2). The study follow-up time ranged from 0.2 to 132 months (Table I). The most frequently reported treatments were surgical excision alone (66.2%) and systemic monotherapy (10.2%), of which minocycline was the most common (Supplementary Table II, available via Mendeley at https://data.mendeley.com/datasets/nvmxbjdnbn/2). Of patients who underwent surgical excision, 48% and 50% attained complete and partial responses, respectively. Of patients treated with minocycline, 20% achieved complete response and 60% had partial response. Overall, 41.8% and 51.6% of the patients achieved complete and partial responses, respectively.Table IStudy-level data and participant demographicsStudy-level dataNTotal studies93Study design, n (%) Case report or series89 (96) Cross-sectional study3 (3) Cohort study1 (1)Participant-level data, n (%)Total number of participants227 M","journal":"JAAD International","year":2023,"id":378316,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9477,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":735850,"name":"Devon Barrett","orcid":"0000-0002-7752-1627","position":1,"is_corresponding":false},{"id":941121,"name":"Ameya Gangal","orcid":"0000-0002-6311-5193","position":2,"is_corresponding":false},{"id":1142257,"name":"Mia S. White","orcid":"0000-0001-5439-1228","position":3,"is_corresponding":false},{"id":526863,"name":"Howa Yeung","orcid":"0000-0002-4815-4936","position":4,"is_corresponding":false},{"id":1142256,"name":"Danielle E. Mustin","orcid":"0000-0002-3212-0264","position":0,"is_corresponding":true}],"reference_count":3,"raw_metadata":null,"created_at":"2026-07-19T01:16:44.708019Z","pmid":"36865613","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}